MFN Drug Pricing Fact Sheet (Nov 6, 2025)

MFN Drug Pricing Fact Sheet (Nov 6, 2025)MFN agreements: White House announces deals with Eli Lilly and Novo Nordisk to align U.S. prices with lowest peer-nation levels via TrumpRx.Big GLP‑1 price cuts:Medicare/Medicaid:Other drugs (TrumpRx pricing):Additional terms: MFN pricing guaranteed on all new medicines from Lilly/Novo; repatriation of increased foreign revenue; MFN access for every state Medicaid program.U.S. manufacturing: Novo Nordisk +$10B (incl. U.S. Wegovy tablet production if approved); Eli Lilly ≥$27B in new U.S. investments.Rationale: Addresses obesity (CDC adult prevalence ~40%) and chronic disease; argues Americans pay >3× OECD brand-name prices and shoulder ~75% of global pharma profits.Timeline of actions: EO on MFN pricing (May 12, 2025); manufacturer letters (Jul 31, 2025); five pricing deals announced since Sep 30, 2025.